{
    "clinical_study": {
        "@rank": "60342", 
        "arm_group": {
            "arm_group_label": "Severe Resistant HTN", 
            "arm_group_type": "Experimental", 
            "description": "Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater"
        }, 
        "brief_summary": {
            "textblock": "The TIVUS II is a prospective, multicenter, non-randomized, open-label clinical study of the\n      safety and performance of the TIVUS\u2122 System consisting of three (3) concurrent cohorts:\n\n        -  TIVUS\u2122 Severe Resistant HTN Cohort\n\n        -  TIVUS\u2122 Moderate Resistant HTN Cohort\n\n        -  TIVUS\u2122 Failed RF Therapy Cohort"
        }, 
        "brief_title": "Continued Safety and Performance of the TIVUS System", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension, Resistant to Conventional Therapy", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is \u2265 18 and \u2264 80 years of age\n\n          -  For Cohort A: Documented office systolic blood pressure > 160 mmHg (> 150 mmHg for\n             diabetic patients); For Cohort B: Documented office systolic blood pressure > 140\n             mmHg (> 130 mmHg for diabetic patients); For Cohort C: Documented office systolic\n             blood pressure > 150 mmHg (> 140 mmHg for diabetic patients)\n\n          -  Documented 24 hour systolic ABPM > 135 mmHg\n\n          -  Adherence to a stable drug regimen\n\n          -  For patients in Cohort C only: Documented renal denervation procedure with any RF\n             technology 12 months or more prior to screening\n\n          -  Suitable renal artery anatomy\n\n          -  Male or non-pregnant / non-lactating female\n\n          -  Patient understands the nature of the procedure and provides written informed consent\n\n          -  Patient is willing and able to comply with the specified study requirements and\n             follow-up evaluations\n\n        Exclusion Criteria:\n\n          -  eGFR < 45mL/min/1.73m2\n\n          -  Documented primary pulmonary hypertension\n\n          -  Patient experienced >1 episode of orthostatic hypotension coupled with syncope\n\n          -  Documented indicator of a secondary renal hypertension\n\n          -  History of myocardial infarction, unstable angina pectoris, or a cerebrovascular\n             accident within 6 months\n\n          -  Planned major surgery or cardiovascular intervention in the next 6 months\n\n          -  Surgery or cardiovascular intervention in the previous 3 months\n\n          -  Hemodynamically significant valvular heart disease\n\n          -  Severe debilitating lung disease\n\n          -  Patient on anticoagulant therapy that cannot be temporarily withheld for performing\n             catheterization\n\n          -  Patient has a single functioning kidney\n\n          -  Documented thrombocytopenia, clotting disorders or aortic aneurysms\n\n          -  Moribund patient, or patient with comorbidities limiting life expectancy to less than\n             one year\n\n          -  Contraindication to recommended study medications or intravascular contrast material\n             that cannot be adequately controlled with pre-medication\n\n          -  Concurrent enrollment in another trial\n\n          -  Main renal arteries < 4 mm in lumen diameter or < 20 mm in length\n\n          -  Aorto-renal angle that prevents a safe cannulation of the renal artery\n\n          -  Severe common femoral artery, common and/or external iliac artery, renal, iliac or\n             aortic calcification or tortuosity that may compromise the safe performance and\n             completion of the procedure\n\n          -  Hemodynamically or anatomically significant renal artery abnormality or stenosis in\n             either renal artery\n\n          -  Any renal artery stenosis > 50% by visual assessment\n\n          -  Any renal artery aneurysm in either renal artery\n\n          -  A history of prior renal artery balloon angioplasty or stenting (for patients in\n             Cohort A and B only, also a history of prior renal denervation at any time)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835535", 
            "org_study_id": "CLN02-001"
        }, 
        "intervention": {
            "arm_group_label": "Severe Resistant HTN", 
            "intervention_name": "TIVUS", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Perth", 
                    "country": "Australia"
                }, 
                "name": "Royal Perth Hospital"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS\u2122) System for Renal Denervation in Patients With Resistant Hypertension", 
        "overall_official": {
            "affiliation": "Kaplan Medical Center", 
            "last_name": "Michael Jonas, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ministry of Health", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Czech Republic: State Institute for Drug Control", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Sweden: Medical Products Agency", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in office Systolic Blood Pressure (SBP) from baseline to 6-month", 
            "safety_issue": "No", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Procedural complications", 
                "safety_issue": "Yes", 
                "time_frame": "30 day"
            }, 
            {
                "measure": "Major Adverse Events (MAE)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Preservation of renal function", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Cardiovascular complications", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Blood pressure reduction", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Cardiosonic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiosonic", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}